Obatoclax
Obatoclax is a small molecule pharmaceutical. It is currently being investigated in clinical studies. It is known to target apoptosis regulator Bcl-2, induced myeloid leukemia cell differentiation protein Mcl-1, and bcl-2-like protein 1.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
19 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Follicular lymphoma | D008224 | C82 | 2 | 2 | — | — | — | 3 | |
| Mantle-cell lymphoma | D020522 | C83.1 | 3 | 2 | — | — | — | 3 | |
| Hodgkin disease | D006689 | C81 | 1 | 1 | — | — | — | 2 | |
| Neoplasms | D009369 | C80 | 2 | 1 | — | — | — | 2 | |
| Leukemia | D007938 | C95 | 1 | 1 | — | — | — | 2 | |
| Multiple myeloma | D009101 | C90.0 | 1 | 1 | — | — | — | 1 | |
| Lung neoplasms | D008175 | C34.90 | 1 | 1 | — | — | — | 1 | |
| Melanoma | D008545 | 1 | 1 | — | — | — | 1 | ||
| Small cell lung carcinoma | D055752 | 1 | 1 | — | — | — | 1 | ||
| B-cell lymphoma marginal zone | D018442 | C88.4 | 1 | 1 | — | — | — | 1 |
Show 3 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| B-cell chronic lymphocytic leukemia | D015451 | C91.1 | 4 | — | — | — | — | 4 | |
| Large b-cell lymphoma diffuse | D016403 | C83.3 | 1 | — | — | — | — | 1 | |
| Prolymphocytic leukemia | D015463 | 1 | — | — | — | — | 1 | ||
| Myeloid leukemia acute | D015470 | C92.0 | 1 | — | — | — | — | 1 | |
| Non-hodgkin lymphoma | D008228 | C85.9 | 1 | — | — | — | — | 1 | |
| Extranodal nk-t-cell lymphoma | D054391 | C86.0 | 1 | — | — | — | — | 1 | |
| Precursor cell lymphoblastic leukemia-lymphoma | D054198 | C91.0 | 1 | — | — | — | — | 1 | |
| Bcr-abl positive chronic myelogenous leukemia | D015464 | EFO_0000340 | 1 | — | — | — | — | 1 | |
| Large-cell lymphoma anaplastic | D017728 | C84.6 | 1 | — | — | — | — | 1 | |
| T-cell lymphoma peripheral | D016411 | C84.9 | 1 | — | — | — | — | 1 |
Show 5 more
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | OBATOCLAX |
| INN | obatoclax |
| Description | Obatoclax mesylate, also known as GX15-070, is an experimental drug for the treatment of various types of cancer. It was discovered by Gemin X, which was acquired by Cephalon, which has since been acquired by Teva Pharmaceuticals. Several Phase II clinical trials were completed that investigated use of Obatoclax in the treatment of leukemia, lymphoma, myelofibrosis, and mastocytosis.
|
| Classification | Small molecule |
| Drug class | bcl-2 (B-cell lymphoma 2) inhibitors |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | COC1=CC(c2cc3ccccc3[nH]2)=N/C1=C\c1[nH]c(C)cc1C |
Identifiers
| PDB | — |
| CAS-ID | 803712-67-6 |
| RxCUI | — |
| ChEMBL ID | CHEMBL408194 |
| ChEBI ID | — |
| PubChem CID | 46930997 |
| DrugBank | DB12191 |
| UNII ID | QN4128B52A (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,760 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
4 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more